Clinical article · Acute care, Specialties

Neutropenic sepsis: antibiotics in the first hour, then risk stratification with MASCC

Written for
Hospital physicians, emergency doctors and residents
Reading time
7 minutes
Published
Updated

Written by the Sana Health team for clinicians. It summarises published guidance, is not a guideline and has not been peer reviewed. Check current local protocols before acting.

Key points

  • Any unwell patient within weeks of myelosuppressive chemotherapy is treated as having neutropenic sepsis until proved otherwise, without waiting for the blood count.
  • Empirical intravenous antipseudomonal beta-lactam therapy should start within an hour of arrival, after blood cultures.
  • Risk stratification with MASCC or CISNE comes after the first antibiotic dose, never instead of it.
  • Selected low-risk adults can be treated with oral antibiotics and as outpatients under a defined local pathway.
  • The empirical regimen should reflect local resistance and the patient's colonisation, and be narrowed when cultures and the clinical course allow.

Treat on suspicion

Febrile neutropenia is one of the most serious toxicities of chemotherapy, with a reported mortality of 2% to 21% [1]. Guidelines define it by fever together with a neutrophil count below 0.5 x 10^9/L, or one expected to fall below that level, with minor differences in the temperature thresholds used [2, 3]. In practice, the decision to treat should not wait for a count: a patient who is unwell within weeks of myelosuppressive chemotherapy is treated as having neutropenic sepsis until proved otherwise.

Fever may be absent. Steroids, paracetamol and older age blunt it, and some patients present only with rigors, hypotension, confusion or a fall. The chemotherapy regimen and the date of the last cycle are the most useful facts in the referral.

The first hour

  1. Assess airway, breathing and circulation, and screen for sepsis with the local early warning tool.
  2. Take blood cultures, from a peripheral vein and from every lumen of any central line, without delaying antibiotics.
  3. Give an empirical intravenous antipseudomonal beta-lactam within an hour of arrival [4, 5], by the local febrile neutropenia policy.
  4. Send a full blood count, renal and liver function, lactate and CRP, with urine and other cultures and a chest radiograph as symptoms direct.
  5. Resuscitate with fluids, and escalate early to critical care if there is shock or organ dysfunction.
  6. Ask about recent cultures and colonisation with resistant organisms, because they change the empirical choice.

Guidelines accept several antipseudomonal beta-lactams as monotherapy, such as piperacillin-tazobactam, cefepime and carbapenems [2, 3]. The European Conference on Infections in Leukaemia now recommends a personalised approach guided by local resistance and individual risk: carbapenem-sparing monotherapy for stable patients without resistant Gram-negative colonisation in low-resistance settings, and broader cover where those conditions are not met [9]. A glycopeptide is added for specific indications, such as suspected catheter infection, skin or soft tissue infection, pneumonia, MRSA colonisation or haemodynamic instability, rather than routinely; the evidence behind its use is limited [2, 10].

Risk stratification with MASCC

Once antibiotics are running, the Multinational Association for Supportive Care in Cancer (MASCC) risk index helps identify adults at low risk of serious complications [6]. It has been used for more than a decade and is named in the ASCO and IDSA guideline alongside clinical judgement [5].

MASCC itemPoints
Burden of illness: no or mild symptoms5
Burden of illness: moderate symptoms3
No hypotension5
No chronic obstructive pulmonary disease4
Solid tumour, or haematological cancer with no previous fungal infection4
No dehydration needing intravenous fluids3
Outpatient at onset of fever3
Age under 60 years2

A total of 21 or more marks low risk. The burden-of-illness item is subjective, and the score performs differently between populations. The Clinical Index of Stable Febrile Neutropenia (CISNE) was designed for apparently stable outpatients with solid tumours, and the accuracy of both scores has been compared in a systematic review and meta-analysis [7]. Neither replaces a clinician's judgement that a patient looks unwell.

Low-risk pathways

Oral antibiotics have proved as effective as intravenous therapy in low-risk febrile neutropenia, and outpatient treatment has been evaluated against inpatient care [8]. The ASCO and IDSA guideline supports outpatient management for selected low-risk adults [5], usually after a period of observation and the first dose given in hospital. The conditions are practical as much as clinical:

  • A low-risk score and no clinical concern
  • Able to take and absorb oral medicines, and no fluoroquinolone prophylaxis already in use
  • A carer at home, a telephone, and transport back to hospital at any hour
  • A named team responsible for follow-up within a short, defined interval

After the first day

Reassess daily. Narrow treatment when cultures identify a cause, and look for a source when fever persists: line infection, perianal or soft tissue infection, Clostridioides difficile, and, in prolonged neutropenia after intensive haematological treatment, invasive fungal infection. In the How Long trial, stopping empirical therapy in haematological patients on clinical criteria, regardless of neutrophil recovery, was tested as a way to avoid unnecessary exposure [11]. Local haematology and oncology protocols decide the duration.

In India and other settings with a high prevalence of extended-spectrum beta-lactamase and carbapenem-resistant Gram-negative bacteria, the local antibiogram and colonisation screening matter even more, and the empirical choice may need to be broader from the start [9]. Tropical infections, including malaria, dengue, enteric fever and tuberculosis, stay in the differential of fever in a patient with cancer.

Children and the traps

Children with cancer have their own international guideline for fever and neutropenia, with paediatric risk tools and regimens, and it should be followed in place of adult rules [12].

  • Waiting for a neutrophil count, or for a fever, before giving antibiotics.
  • Calculating a risk score before the first dose.
  • Missing cultures from each central line lumen.
  • Routine vancomycin without an indication, or omitting it in shock or line infection.
  • Forgetting previous resistant isolates when choosing the empirical drug.
  • Sending a patient home without a safe outpatient pathway behind the decision.

Antibiotic choice, timing targets and outpatient criteria vary between national guidelines and hospital policies. The local febrile neutropenia protocol takes precedence.

How Sana Health helps

Given the regimen, the date of the last cycle, observations, the neutrophil count if known and any previous resistant organisms, the Oncology engine treats the presentation as neutropenic sepsis on suspicion and lists the first-hour actions first. It then calculates the MASCC score with each item shown, states whether a low-risk pathway might be considered under local protocol, and sets out what to reassess at 48 to 72 hours. References are read from PubMed when the question is asked, and the local febrile neutropenia policy takes precedence.

Questions

What is the time to antibiotics target in neutropenic sepsis?

Most guidelines and hospital pathways aim to give the first dose of an empirical intravenous antibiotic within an hour of arrival, after blood cultures and without waiting for the blood count. Local policies define the exact standard and how it is measured.

What MASCC score is low risk?

A MASCC score of 21 or more identifies adults at low risk of serious complications. It is calculated after the first antibiotic dose and is used with clinical judgement, not as the only basis for outpatient treatment.

Should vancomycin be added for febrile neutropenia?

Not routinely. It is added for specific indications such as suspected catheter-related infection, skin or soft tissue infection, pneumonia, MRSA colonisation or haemodynamic instability, and stopped when cultures do not support it.

References

  1. Prophylactic antibiotics or G(M)-CSF for the prevention of infections and improvement of survival in cancer patients receiving myelotoxic chemotherapy (opens in a new tab)Cochrane Database Syst Rev, 2015
  2. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america (opens in a new tab)Clin Infect Dis, 2011
  3. Management of febrile neutropenia: ESMO Clinical Practice Guidelines (opens in a new tab)Ann Oncol, 2010
  4. Timing of antibiotic initiation in sepsis and neutropenic fever (opens in a new tab)Front Med (Lausanne), 2025
  5. Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update (opens in a new tab)J Clin Oncol, 2018
  6. The Multinational Association for Supportive Care in Cancer (MASCC) risk index score: 10 years of use for identifying low-risk febrile neutropenic cancer patients (opens in a new tab)Support Care Cancer, 2013
  7. Accuracy of the Multinational Association of Supportive Care in Cancer (MASCC) and Clinical Index of Stable Febrile Neutropenia (CISNE) scores for predicting serious complications in adult patients with febrile neutropenia: A systematic review and meta-analysis (opens in a new tab)Crit Rev Oncol Hematol, 2020
  8. Outpatient treatment for people with cancer who develop a low-risk febrile neutropaenic event (opens in a new tab)Cochrane Database Syst Rev, 2019
  9. Empirical and targeted antimicrobial therapy in patients with febrile neutropenia and haematological malignancy or after haematopoietic cell transplantation: recommendations from the 10th European Conference on Infections in Leukaemia (opens in a new tab)Lancet Infect Dis, 2026
  10. Shock and Early Death in Hematologic Patients with Febrile Neutropenia (opens in a new tab)Antimicrob Agents Chemother, 2019
  11. Optimisation of empirical antimicrobial therapy in patients with haematological malignancies and febrile neutropenia (How Long study): an open-label, randomised, controlled phase 4 trial (opens in a new tab)Lancet Haematol, 2017
  12. Guideline for the Management of Fever and Neutropenia in Pediatric Patients With Cancer and Hematopoietic Cell Transplantation Recipients: 2023 Update (opens in a new tab)J Clin Oncol, 2023